
|Articles|March 1, 2004
Drug exposure tested
Washington -- In the treatment of moderate-to-severe atopic dermatitis, pimecrolimus (Elidel) cream 1 percent is less likely than tacrolimus (Protopic) ointment 0.1 percent to be systemically absorbed, according to Zoe Draelos, M.D., lead investigator of a blind treatment trial that compared systemic exposure levels of the two topical drugs.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Shows Durable Skin Clearance in Phase 3 Psoriasis Extension
2
The Emerging Role of Oral Peptide Therapeutics in Psoriasis and Beyond
3
Social Media Mythbusters: Hydrocolloid Pimple Patches
4
Allergan Aesthetics Refreshes APP Loyalty Program for Aesthetic Practices
5










